

Clinical trials of nesiritide

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
nesiritide vs control			
NSGET (comparative trial) , 2000 n=203/102 follow-up: <5 days	nesiritide(0.015 and 0.030 microg/kg/min versus usual care	acutely decompensated heart failure requiring invasive monitoring	Parallel groups open US
nesiritide vs placebo			
ASCEND-HF , 2011 <i>unpublished</i> [NCT00475852] n=3496/3511 follow-up: 30 days	intravenous nesiritide for 24 hours to 7 days on top of standard therapy versus matching placebo	Patients hospitalized for heart failure (within 24 hours of hospitalization and institution of acute IV therapy for ADHF)	Parallel groups double-blind North America, Europe, Latin America, Asia-Pacific region
BNP-CARDS , 2007 [NCT00186329] n=39/36 follow-up: 7 days	nesiritide as a 0.01-g/kg/min infusion for 48 hours versus placebo	acute decompensated heart failure with moderate to severe renal insufficiency	Parallel groups Double blind US
FUSION 2 , 2008 [NCT00091520] n=911 follow-up: 12 weeks	nesiritide (2 g/kg bolus plus 0.01 g/kg-per-minute infusion for four to six hours) versus placebo	patients with ACC/AHA stage C/D heart failure with two recent heart-failure hospitalizations, an ejection fraction of less than 40% , and NYHA class 4 symptoms or NYHA class 3 symptoms with creatinine clearance less than 60 mL/min	Parallel groups double-blind
NSGET (efficacy trial) , 2000 n=85/42 follow-up:	nesiritide(0.015 and 0.030 microg/kg/min versus placebo	acutely decompensated heart failure requiring invasive monitoring	
PROACTION , 2003 n=127/123 follow-up: 30 days	nesiritidefor at least 12h versus placebo	patients presenting to the ED with acutely decompensated HF and dyspnea at rest or with minimal activity	Parallel groups double-blind USA

continued...

Trial	Treatments	Patients	Trials design and methods
VMAC (intravenous nesiritide) , 2002 [NCT00083772] n=204/142 follow-up:	intravenous nesiritide for 3 hours versus placebo	acutely decompensated heart failure requiring hospitalization	double-blind USA
nesiritide vs dobutamine			
PRECEDENT , 2002 [NCT00270400] n=NA follow-up:	nesiritide(0.015 or 0.03 microg/kg/min) versus Dobutamine (>or =5 microg/kg/min)	Symptomatic, Decompensated CHF	Parallel groups open
nesiritide vs nitroglycerin			
VMAC (24h) , 2002 [NCT00083772] n=280/218 follow-up:	nesiritide infusion for 24 hours versus nitroglycerin	acutely decompensated heart failure requiring hospitalization	
nesiritide vs standard care			
FUSION 1 , 2004 [NCT00270361] n=NA follow-up: 12 weeks	nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly versus standard care	outpatient with co-morbid advanced heart failure and renal insufficiency	Parallel groups open

More details and results :

- vasodilators therapy for heart failure in all type of patient at <http://www.trialresultscenter.org/go-Q79>
- vasodilators therapy for heart failure in acute decompensated heart failure at <http://www.trialresultscenter.org/go-Q472>

References

NSGET (comparative trial), 2000:

Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH N Engl J Med 2000 Jul 27;343:246-53 [10911006]

ASCEND-HF, 2011:

unpublished

Burnett JC Jr, Korinek J The tumultuous journey of nesiritide: past, present, and future. Circ Heart Fail 2008 May;1:6-8 [19808264] [10.1161/CIRCHEARTFAILURE.108.776294](https://doi.org/10.1161/CIRCHEARTFAILURE.108.776294)

Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 2009 Feb;157:271-7 [19185633]

O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausel Effect of nesiritide in patients with acute decompensated heart failure. *N Engl J Med* 2011 Jul 7;365:32-43 [[21732835](#)] [10.1056/NEJMoa1100171](#)

BNP-CARDS, 2007:

Witteles RM, Kao D, Vagelos R, et al. Nesiritide does not cause renal dysfunction in acute decompensated heart failure: A randomized, double-blind, placebo-controlled study. *American College of Cardiology 2007 Scientific Sessions*; March 26, 2007; New Orleans, LA. Abstract 808-4 [[0](#)]

Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. *JAMA* 2005;293:1900-5 [[15840865](#)] [10.1001/jama.293.15.1900](#)

Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, Fowler MB Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. *J Am Coll Cardiol* 2007;50:1835-40 [[17980248](#)] [10.1016/j.jacc.2007.03.071](#)

FUSION 2, 2008:

Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. *Am Heart J* 2007;153:478-84 [[17383282](#)]

Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. *Circ Heart Fail* 2008;1:9-16 [[19808265](#)] [10.1161/CIRCHEARTFAILURE.108.767483](#)

NSGET (efficacy trial), 2000:

Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. *N Engl J Med* 2000 Jul 27;343:246-53 [[10911006](#)]

PROACTION, 2003:

Peacock W, Emerman C the PROACTION Study Group. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients *J Am Coll Cardiol*. 2003;41:336A.

Peacock WF 4th, Holland R, Gyarmathy R, Dunbar L, Klapholz M, Horton DP, de Lissovoy G, Emerman CL Observation unit treatment of heart failure with nesiritide: results from the proaction trial. *J Emerg Med* 2005;29:243-52 [[16183441](#)] [10.1016/j.jemermed.2005.01.024](#)

VMAC (intravenous nesiritide), 2002:

JAMA 2002 Mar 27;287:1531-40 [[11911755](#)]

PRECEDENT, 2002:

Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng ML, Elkayam U Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. *Am Heart J* 2002;144:1102-8 [[12486437](#)]

VMAC (24h), 2002:

Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. *JAMA* 2002 Mar 27;287:1531-40 [[11911755](#)]

FUSION 1, 2004:

Yancy CW, Singh A Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol 2006 Jul 15;98:226-9 [16828598]

Yancy CW, Saltzberg MT, Berkowitz RL, Bertolet B, Vijayaraghavan K, Burnham K, Oren RM, Walker K, Horton DP, Silver MA Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004 Sep 1;94:595-601 [15342289]

Yancy CW, Singh A Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol 2006 Jul 15;98:226-9 [16828598]

2 acute heart failure

Trial	Treatments	Patients	Trials design and methods
nesiritide vs control			
NSGET (comparative trial) , 2000 n=203/102 follow-up: <5 days	nesiritide(0.015 and 0.030 microg/kg/min versus usual care	acutely decompensated heart failure requiring invasive monitoring	Parallel groups open US
nesiritide vs placebo			
ASCEND-HF , 2011 <i>unpublished</i> [NCT00475852] n=3496/3511 follow-up: 30 days	intravenous nesiritide for 24 hours to 7 days on top of standard therapy versus matching placebo	Patients hospitalized for heart failure (within 24 hours of hospitalization and institution of acute IV therapy for ADHF)	Parallel groups double-blind North America, Europe, Latin America, Asia-Pacific region
BNP-CARDS , 2007 [NCT00186329] n=39/36 follow-up: 7 days	nesiritide as a 0.01-g/kg/min infusion for 48 hours versus placebo	acute decompensated heart failure with moderate to severe renal insufficiency	Parallel groups Double blind US
FUSION 2 , 2008 [NCT00091520] n=911 follow-up: 12 weeks	nesiritide (2 g/kg bolus plus 0.01 g/kg-per-minute infusion for four to six hours) versus placebo	patients with ACC/AHA stage C/D heart failure with two recent heart-failure hospitalizations, an ejection fraction of less than 40% , and NYHA class 4 symptoms or NYHA class 3 symptoms with creatinine clearance less than 60 mL/min	Parallel groups double-blind
NSGET (efficacy trial) , 2000 n=85/42 follow-up:	nesiritide(0.015 and 0.030 microg/kg/min versus placebo	acutely decompensated heart failure requiring invasive monitoring	

continued...

Trial	Treatments	Patients	Trials design and methods
PROACTION , 2003 n=127/123 follow-up: 30 days	nesiritidefor at least 12h versus placebo	patients presenting to the ED with acutely decompensated HF and dyspnea at rest or with minimal activity	Parallel groups double-blind USA
VMAC (intravenous nesiritide) , 2002 [NCT00083772] n=204/142 follow-up:	intravenous nesiritidefor 3 hours versus placebo	acutely decompensated heart failure requiring hospitalization	double-blind USA
nesiritide vs dobutamine			
PRECEDENT , 2002 [NCT00270400] n=NA follow-up:	nesiritide(0.015 or 0.03 microg/kg/min) versus Dobutamine (>or =5 microg/kg/min)	Symptomatic, Decompensated CHF	Parallel groups open
nesiritide vs nitroglycerin			
VMAC (24h) , 2002 [NCT00083772] n=280/218 follow-up:	nesiritideinfusion for 24 hours versus nitroglycerin	acutely decompensated heart failure requiring hospitalization	
nesiritide vs standard care			
FUSION 1 , 2004 [NCT00270361] n=NA follow-up: 12 weeks	nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly versus standard care	outpatient with co-morbid advanced heart failure and renal insufficiency	Parallel groups open

More details and results :

- new drug under development for acute heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q640>
- endothelin receptor antagonist for acute heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q643>
- atrial natriuretic peptide for acute heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q644>

References

NSGET (comparative trial), 2000:

Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH N Engl J Med 2000 Jul 27;343:246-53 [10911006]

ASCEND-HF, 2011:

unpublished

Burnett JC Jr, Korinek J The tumultuous journey of nesiritide: past, present, and future. *Circ Heart Fail* 2008 May;1:6-8 [[19808264](#)] [10.1161/CIRCHEARTFAILURE.108.776294](#)

Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). *Am Heart J* 2009 Feb;157:271-7 [[19185633](#)]

O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausel Effect of nesiritide in patients with acute decompensated heart failure. *N Engl J Med* 2011 Jul 7;365:32-43 [[21732835](#)] [10.1056/NEJMoa1100171](#)

BNP-CARDS, 2007:

Witteles RM, Kao D, Vagelos R, et al. Nesiritide does not cause renal dysfunction in acute decompensated heart failure: A randomized, double-blind, placebo-controlled study. American College of Cardiology 2007 Scientific Sessions; March 26, 2007; New Orleans, LA. Abstract 808-4 [0]

Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. *JAMA* 2005;293:1900-5 [[15840865](#)] [10.1001/jama.293.15.1900](#)

Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, Fowler MB Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. *J Am Coll Cardiol* 2007;50:1835-40 [[17980248](#)] [10.1016/j.jacc.2007.03.071](#)

FUSION 2, 2008:

Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. *Am Heart J* 2007;153:478-84 [[17383282](#)]

Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. *Circ Heart Fail* 2008;1:9-16 [[19808265](#)] [10.1161/CIRCHEARTFAILURE.108.767483](#)

NSGET (efficacy trial), 2000:

Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. *N Engl J Med* 2000 Jul 27;343:246-53 [[10911006](#)]

PROACTION, 2003:

Peacock W, Emerman C the PROACTION Study Group. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients *J Am Coll Cardiol*. 2003;41:336A.

Peacock WF 4th, Holland R, Gyarmathy R, Dunbar L, Klapholz M, Horton DP, de Lissovoy G, Emerman CL Observation unit treatment of heart failure with nesiritide: results from the proaction trial. *J Emerg Med* 2005;29:243-52 [[16183441](#)] [10.1016/j.jemermed.2005.01.024](#)

VMAC (intravenous nesiritide), 2002:

JAMA 2002 Mar 27;287:1531-40 [[11911755](#)]

PRECEDENT, 2002:

Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng ML, Elkayam U Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. *Am Heart J* 2002;144:1102-8 [[12486437](#)]

VMAC (24h), 2002:

Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002 Mar 27;287:1531-40 [11911755]

FUSION 1, 2004:

Yancy CW, Singh A Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol 2006 Jul 15;98:226-9 [16828598]

Yancy CW, Saltzberg MT, Berkowitz RL, Bertolet B, Vijayaraghavan K, Burnham K, Oren RM, Walker K, Horton DP, Silver MA Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004 Sep 1;94:595-601 [15342289]

Yancy CW, Singh A Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol 2006 Jul 15;98:226-9 [16828598]

Entry terms: Brain Natriuretic Peptide, BNP-32, BNP 32, Nesiritide, B-Type Natriuretic Peptide, BNP Gene Product, Type-B Natriuretic Peptide, Type B Natriuretic Peptide, Natriuretic Peptide Type-B, Natriuretic Peptide Type B, Natriuretic Factor-32, Natriuretic Factor 32, Brain Natriuretic Peptide-32, Brain Natriuretic Peptide 32, Natrecor,